NeoGenomics, Inc.

NasdaqCM:NEO Stock Report

Market Cap: US$1.3b

NeoGenomics Future Growth

Future criteria checks 1/6

NeoGenomics is forecast to grow earnings and revenue by 17.5% and 10.4% per annum respectively. EPS is expected to grow by 19.7% per annum. Return on equity is forecast to be 7.2% in 3 years.

Key information

17.5%

Earnings growth rate

19.7%

EPS growth rate

Healthcare earnings growth14.0%
Revenue growth rate10.4%
Future return on equity7.2%
Analyst coverage

Good

Last updated21 Apr 2025

Recent future growth updates

Recent updates

author-image

PanTracer Launch And MRD Collaboration Will Strengthen Future Cancer Testing Leadership

Mar 23 NeoGenomics' strategic investments and collaborations are expected to enhance customer experiences, boost test volumes, and strengthen competitive positioning in MRD monitoring and Heme testing.

NeoGenomics, Inc.'s (NASDAQ:NEO) Stock Retreats 28% But Revenues Haven't Escaped The Attention Of Investors

Mar 08
NeoGenomics, Inc.'s (NASDAQ:NEO) Stock Retreats 28% But Revenues Haven't Escaped The Attention Of Investors

NeoGenomics: Decent Fundamentals, But Still Overvalued

Feb 28

Here's Why NeoGenomics (NASDAQ:NEO) Can Afford Some Debt

Feb 18
Here's Why NeoGenomics (NASDAQ:NEO) Can Afford Some Debt

What You Can Learn From NeoGenomics, Inc.'s (NASDAQ:NEO) P/S After Its 29% Share Price Crash

Jan 14
What You Can Learn From NeoGenomics, Inc.'s (NASDAQ:NEO) P/S After Its 29% Share Price Crash

NeoGenomics, Inc. (NASDAQ:NEO) Stocks Shoot Up 25% But Its P/S Still Looks Reasonable

Nov 23
NeoGenomics, Inc. (NASDAQ:NEO) Stocks Shoot Up 25% But Its P/S Still Looks Reasonable

Is NeoGenomics (NASDAQ:NEO) A Risky Investment?

Oct 16
Is NeoGenomics (NASDAQ:NEO) A Risky Investment?

Investors Appear Satisfied With NeoGenomics, Inc.'s (NASDAQ:NEO) Prospects As Shares Rocket 29%

Aug 01
Investors Appear Satisfied With NeoGenomics, Inc.'s (NASDAQ:NEO) Prospects As Shares Rocket 29%

Is NeoGenomics (NASDAQ:NEO) A Risky Investment?

Jul 15
Is NeoGenomics (NASDAQ:NEO) A Risky Investment?

Investors Interested In NeoGenomics, Inc.'s (NASDAQ:NEO) Revenues

Mar 30
Investors Interested In NeoGenomics, Inc.'s (NASDAQ:NEO) Revenues

Investor Optimism Abounds NeoGenomics, Inc. (NASDAQ:NEO) But Growth Is Lacking

Dec 26
Investor Optimism Abounds NeoGenomics, Inc. (NASDAQ:NEO) But Growth Is Lacking

Is NeoGenomics (NASDAQ:NEO) A Risky Investment?

Aug 23
Is NeoGenomics (NASDAQ:NEO) A Risky Investment?

Risks To Shareholder Returns Are Elevated At These Prices For NeoGenomics, Inc. (NASDAQ:NEO)

Jul 16
Risks To Shareholder Returns Are Elevated At These Prices For NeoGenomics, Inc. (NASDAQ:NEO)

NeoGenomics (NASDAQ:NEO) Is Making Moderate Use Of Debt

Apr 18
NeoGenomics (NASDAQ:NEO) Is Making Moderate Use Of Debt

We Think NeoGenomics (NASDAQ:NEO) Has A Fair Chunk Of Debt

Jan 10
We Think NeoGenomics (NASDAQ:NEO) Has A Fair Chunk Of Debt

NeoGenomics: Market Punishment Continues, But Looks Justified

Sep 30

NeoGenomics grants CEO restricted shares, stock options

Aug 17

Here's Why NeoGenomics (NASDAQ:NEO) Can Afford Some Debt

Aug 10
Here's Why NeoGenomics (NASDAQ:NEO) Can Afford Some Debt

NeoGenomics rises ~14% on strong Q2 result

Aug 09

NeoGenomics gets new CEO

Jul 21

NeoGenomics: Refrain From Portfolio Allocation, Negligible Upside Potential

Jun 28

Earnings and Revenue Growth Forecasts

NasdaqCM:NEO - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2027917-5180N/A6
12/31/2026821-54239514
12/31/2025738-79-462614
12/31/2024661-79-347N/A
9/30/2024644-78-2215N/A
6/30/2024628-79-300N/A
3/31/2024611-84-40-15N/A
12/31/2023592-88-31-2N/A
9/30/2023575-96-50-23N/A
6/30/2023552-115-64-34N/A
3/31/2023530-126-82-50N/A
12/31/2022510-144-97-66N/A
9/30/2022497-163-120-82N/A
6/30/2022489-147-119-74N/A
3/31/2022486-36-115-58N/A
12/31/2021484-8-91-27N/A
9/30/202148549-65-1N/A
6/30/202148972-497N/A
3/31/2021454-11-3011N/A
12/31/20204444-281N/A
9/30/2020425-5-25-1N/A
6/30/2020405-5-617N/A
3/31/20204193-1110N/A
12/31/20194098323N/A
9/30/201937821835N/A
6/30/201934321325N/A
3/31/201930962437N/A
12/31/201827763045N/A
9/30/20182628N/A35N/A
6/30/2018252-1N/A34N/A
3/31/2018246-9N/A34N/A
12/31/2017240-11N/A18N/A
9/30/2017239-27N/A12N/A
6/30/2017241-26N/A14N/A
3/31/2017242-29N/A13N/A
12/31/2016232-31N/A21N/A
9/30/2016211-18N/A24N/A
6/30/2016175-12N/A17N/A
3/31/2016136-7N/A14N/A
12/31/2015100-3N/A6N/A
9/30/2015980N/A5N/A
6/30/2015960N/A6N/A
3/31/2015920N/A8N/A
12/31/2014871N/A9N/A
9/30/2014801N/A8N/A
6/30/2014742N/A7N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: NEO is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: NEO is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: NEO is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: NEO's revenue (10.4% per year) is forecast to grow faster than the US market (8.2% per year).

High Growth Revenue: NEO's revenue (10.4% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: NEO's Return on Equity is forecast to be low in 3 years time (7.2%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/04/27 07:29
End of Day Share Price 2025/04/25 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

NeoGenomics, Inc. is covered by 28 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Bruce JacksonBenchmark Company
Raymond MyersBenchmark Company
Michael RyskinBofA Global Research